Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Neda Stjepanovic
Jaume Capdevila
Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

Abstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.

Keywords: thyroid cancer, lenvatinib, tyrosine kinase inhibitors, multikinase inhibitors, targeted therapies

Introduction
Thyroid cancer is the most prevalent endocrine malignancy and its incidence has been steadily increasing over the last three decades.¹ This increase in incidence rate could reflect either increased detection or a true increase due to environment and lifestyle changes.² Compared with other regions in the world, the highest incidence of thyroid cancer occurs in the female population of Northern America, which has an age-standardized rate of 15.1 per 100,000 females, while in Western Europe the age-standardized rate is 5.8 per 100,000 females.³

Histopathologically, thyroid cancers are classified into three groups, ie, differentiated thyroid carcinoma (DTC) representing 94% of all thyroid cancers and including the three subtypes of papillary (80%), follicular (11%) and Hurthle cell carcinoma (3%), with medullary thyroid carcinoma (MTC) representing 4% and anaplastic (undifferentiated) thyroid carcinoma (ATC) representing the remaining 2%.⁴

The prognosis is excellent for the majority of patients treated by surgery, thyroid-stimulating hormone-suppressive therapy, and radioiodine ablation in the case of DTC, with an overall survival rate of 97.7% at 5 years.⁵ Nevertheless, local recurrence occurs in up to 20% of patients, and distant metastases in approximately 10% at 10 years.⁶ The natural evolution of relapsed thyroid cancer is towards metastatic dissemination and loss of ability to take up iodine, leading to a lack of response to
the afore-mentioned standard therapies and an overall survival rate of less than 15% at 10 years. The only approved systemic cytotoxic therapy for DTC is doxorubicin, which has a low response rate and an unfavorable toxicity profile, and no targeted treatments have been approved as yet for this type of thyroid cancer. Patients with advanced MTC derive limited benefit from cytotoxic drugs; however, in the last 3 years, due to enormous efforts and international collaboration, two targeted treatments have been approved for this type of thyroid cancer, ie, vandetanib and more recently cabozantinib.

Because of the lack of efficacy of traditional cytotoxic agents, novel treatments are needed for patients with thyroid cancer, especially for radioiodine-refractory and metastatic DTC. For the development of such new drugs, knowledge of the molecular pathways involved in the carcinogenesis of thyroid tumors is crucial.

Among the new therapeutic approaches for patients with advanced DTC, the most promising are the multikinase inhibitors, such as sorafenib, sunitinib, axitinib, vandetanib, pazopanib, and lenvatinib. Other novel treatments being evaluated include histone deacetylase inhibitors (vorinostat anddepsipeptide), a DNA methylation inhibitor (decitabine), a heat-shock protein 90 inhibitor (17-AAG), a proteasome inhibitor (bortezomib), a selective cyclooxygenase-2 inhibitor (celecoxib), a derivative of thalidomide (lenalidomide), and mammalian target of rapamycin (mTOR) inhibitors (such as everolimus alone or in combination with multikinase inhibitors).

This review focuses on multikinase inhibitors and the specific role of lenvatinib in the treatment of advanced thyroid cancer.

**Tyrosine kinases and molecular pathways in thyroid carcinoma**

Tyrosine kinases are enzymes that carry out protein phosphorylation, an important mechanism in cellular signal transduction in pathways that control cell proliferation, differentiation, migration, metabolism, and apoptosis. Tyrosine kinases are classified into two groups, ie, tyrosine kinase receptors (TKR), that are proteins located at the cell membrane and transduct extracellular signals to the cytoplasm when activated by ligands, and cellular tyrosine kinases that relay intracellular signals.

In cancer cells, constitutive activation of a pathway that leads to continuous oncogenic signaling can be a result of somatic or germline genetic alterations that cause overexpression or mutation of tyrosine kinases or other intracellular signals. Thyroid tumors frequently have genetic alterations leading to activation of the RET/PTC-RAS-RAF-MAPK axis and phosphatidylinositol-3-kinase (PI3K)-AKT-mTOR pathway (Figure 1).

The proto-oncogene RET (rearranged during transfection) encodes a membrane TKR, so rearrangements in the RET gene (RET/PTC) can lead to oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway and development of cancer. Distally on the same pathway, activating mutations in RAS and RAF protein kinases can also have the same result. More than 70% of papillary thyroid carcinomas (PTC) harbor point mutations of BRAF and RAS genes (40%-50% and 10%, respectively) and RET/PTC rearrangement (30%-40%), alterations that rarely overlap in the same tumor.

The most frequent alterations found in follicular thyroid carcinomas (FTC) are RAS mutations (40%-50%) and paired box 8/peroxisome proliferator-activated receptor gamma (PAX8/PPARγ) rearrangements (35%). PAX8/PPARγ rearrangements result in a fusion oncogene that consists of the PAX8 gene, a thyroid-specific transcription factor, and the PPARγ gene, a ubiquitously expressed transcription factor. This oncogene accelerates cell growth, reduces apoptosis, and permits independent growth of thyroid cell lines.

Genetic alterations in PI3K-regulated intracellular signals and constitutive activation of the intracellular pathway downstream PI3K are frequent in more aggressive variants of thyroid cancer, such as poorly DTC and ATC. Pathway activation can be secondary to gene amplification of the serine-threonine-protein-kinase AKT, activating mutations in the PI3K catalytic subunit (both more frequent in FTC and ATC than in PTC), or amplification of PIK3CA (16% of PTC, 30% of FTC, and 50% of ATC).

In familial MTC and the multiple endocrine neoplasia type 2 syndromes, a germline mutation causes activation of RET kinase and consequent activation of RAS, which leads to cross-activation of the MAPK and PI3K pathways. In sporadic MTC, about 50% of cases have amplified RAS-RAF signaling, leading also to cross-activation of the MAPK and PI3K pathway.

RET is the most studied targetable TKR involved in the tumorigenesis of thyroid carcinoma, and is known to be able to activate a variety of signaling cascades, including MAPK and PI3K-AKT. Other TKR capable of activating the same pathways have been described, and include epidermal growth factor receptor, the vascular endothelial growth factor receptor (VEGFR) family, the fibroblast growth factor receptor
The VEGFR family has three members, ie, VEGFR-1, VEGFR-2, and VEGFR-3, and their increased expression is characteristic of DTC.\textsuperscript{25,26} The VEGFR family is associated with increased tumor growth, progression, and invasiveness, and with decreased recurrence-free survival. VEGFR-2 is the most important mediator of tumor angiogenesis,\textsuperscript{27} while VEGFR-3 is expressed mainly in lymphatic endothelial cells, and is thought to be primarily involved in lymphangiogenesis.

The FGFR family has four members, ie, FGFR-1, FGFR-2, FGFR-3, and FGFR-4, which are well known to be expressed in thyroid cancers.\textsuperscript{28} The principal functions of FGFR are regulation of cell growth, proliferation, differentiation, and survival.\textsuperscript{29,30} In thyroid cancers, expression of FGFR-2 is diminished, indicating its protective role, and the rest of the receptors are overexpressed. While FGFR-1 and FGFR-3 are overexpressed in well differentiated tumors, FGFR-4 is overexpressed in more aggressive tumors, suggesting its role in tumor progression.\textsuperscript{31}

**Tyrosine kinase inhibitors and resistance**

Thyroid cancers with constitutive activation in a pathway secondary to TKR alteration can be sensitive to two types of specific inhibitors of the implied tyrosine kinase, ie, monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs).

The benefits of TKR inhibitors can be inexisten or transient, due to distinct mechanisms of drugs resistance followed by tumor progression. Two modes of resistance have been described for the VEGF pathway inhibitors: intrinsic, manifesting no benefit from the drug, and evasive, reflecting the capacity of the tumor to avoid blockade of angiogenesis. Intrinsic resistance may be explained by the pre-existing tumor microenvironment that confers
the indifference to the drug. Evasive resistance involves numerous mechanisms such as: upregulation of alternative proangiogenic signals leading to revascularization; recruitment of proangiogenic inflammatory cells or pericyte coverage providing protection for the tumor vasculature; local tissue invasion acquiring vascularization from normal vasculature; and, finally, metastasis to lymph nodes and distant organs.32

Among the alternative proangiogenic signals, upregulation of FGF/FGFRs has been described. Recent data from preclinical studies suggest that the FGFR pathway is a driver of resistance to antiangiogenic drugs, so anti-FGF/FGFR agents can be used to reverse acquired resistance to anti-VEGFR or other targeted agents.33

Considering that most solid tumors show deregulation of multiple signaling pathways and upregulation of pathways as a mechanism of resistance, combinations of various TKIs with different targets have been investigated in preclinical and clinical studies with positive results. For these reasons, current drug development tends to focus on creating a single drug capable of targeting several tyrosine kinases and oncogenic pathways simultaneously, ie, a multikinase inhibitor.

**Multikinase inhibitors in thyroid carcinoma**

Recent studies of multikinase inhibitors in advanced thyroid carcinoma have shown prolonged tumor response and clinical benefit (Table 1), causing a shift in the treatment of this group of patients. The effectiveness of these drugs can be explained by their ability to inhibit several pathways simultaneously (like PI3K and MAPK, the two most important pathways in thyroid carcinoma) and their role as inhibitors of angiogenesis. Several of these agents are currently under clinical investigation in patients with DTC and MTC, and some have already been approved for treatment of advanced MTC.

Motesanib diphosphate is an oral inhibitor of the tyrosine kinases of VEGFR-1, VEGFR-2, VEGFR-3, the platelet-derived growth factor receptor (PDGFR), c-KIT, and wild-type RET.41 Two Phase II trials using motesanib diphosphate 125 mg once daily have been conducted in patients with advanced or metastatic thyroid cancer. The first trial included

### Table 1 Main studies in advanced thyroid cancer with targeted therapies.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Drug</th>
<th>Phase</th>
<th>N</th>
<th>Tumor type</th>
<th>RR%</th>
<th>SD%</th>
<th>mPFS, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sherman et al, 2008a</td>
<td>Motesanib</td>
<td>2</td>
<td>93</td>
<td>DTC</td>
<td>14</td>
<td>35*</td>
<td>9.2</td>
</tr>
<tr>
<td>Schlumberger et al, 2009b</td>
<td>Motesanib</td>
<td>2</td>
<td>91</td>
<td>MTC</td>
<td>2</td>
<td>48*</td>
<td>11</td>
</tr>
<tr>
<td>Cohen et al, 2008c</td>
<td>Axitinib</td>
<td>2</td>
<td>60</td>
<td>All</td>
<td>30</td>
<td>38</td>
<td>18.1</td>
</tr>
<tr>
<td>Locati et al, 2012a</td>
<td>Axitinib</td>
<td>2</td>
<td>52</td>
<td>DTC, MTC</td>
<td>34.6</td>
<td>34.6</td>
<td>NR</td>
</tr>
<tr>
<td>Kloos et al, 2009a</td>
<td>Sorafenib</td>
<td>2</td>
<td>41</td>
<td>PTC</td>
<td>15</td>
<td>56*</td>
<td>16</td>
</tr>
<tr>
<td>Gupta-Abramson et al, 2008b</td>
<td>Sorafenib</td>
<td>2</td>
<td>30</td>
<td>DTC</td>
<td>23</td>
<td>53</td>
<td>19.3</td>
</tr>
<tr>
<td>Hofitser et al, 2009c</td>
<td>Sorafenib</td>
<td>2</td>
<td>31</td>
<td>DTC</td>
<td>25</td>
<td>34</td>
<td>14.5</td>
</tr>
<tr>
<td>Ahmed et al, 2011d</td>
<td>Sorafenib</td>
<td>2</td>
<td>26</td>
<td>DTC, MTC</td>
<td>18</td>
<td>82</td>
<td>NR</td>
</tr>
<tr>
<td>Brose M et al, 2013e</td>
<td>Sorafenib vs. Placebo</td>
<td>3</td>
<td>417</td>
<td>DTC</td>
<td>12.2 vs. 0.5</td>
<td>42vs.33*</td>
<td>10.8 vs. 5.8</td>
</tr>
<tr>
<td>Lam et al, 2010f</td>
<td>Sorafenib</td>
<td>2</td>
<td>15</td>
<td>MTC</td>
<td>6</td>
<td>88</td>
<td>17.9</td>
</tr>
<tr>
<td>Capdevila et al, 2012g</td>
<td>Sorafenib</td>
<td>R</td>
<td>34</td>
<td>MTC</td>
<td>47</td>
<td>40</td>
<td>10.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DTC</td>
<td>19</td>
<td>50</td>
<td>13.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ATC</td>
<td>33</td>
<td>0</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>35</td>
<td>57</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>49</td>
<td>NR</td>
<td>11.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>0</td>
<td>NR</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>20</td>
<td>53</td>
<td>27.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>16</td>
<td>53*</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>45 vs. 13</td>
<td>145vs.139</td>
<td>30.5 vs. 19.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>8.3</td>
<td>NR</td>
<td>11.1 vs. 5.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>29</td>
<td>41</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTC</td>
<td>28 vs. 0</td>
<td>NR</td>
<td>11.2 vs. 4.1</td>
</tr>
</tbody>
</table>

Abbreviations: NR, not reported or not reached; R, retrospective study; a: >6 m; b: sporadic; c: hereditary; d: results given for the DTC group; e: patients with 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography-avid thyroid cancers.
93 patients with advanced radioiodine-resistant DTC. The objective response rate was 14%, and stable disease was maintained for 24 weeks or longer in 35% of patients. Among those who progressed, median progression-free survival was 40 weeks. Serum thyroglobulin levels decreased by more than 50% in 45% of patients (in 15% beyond 24 weeks), and this biomarker response correlated with radiological response. The second trial included 91 patients with advanced MTC, with a partial response achieved in 2%, stable disease beyond 24 weeks in 48%, and a median progression-free survival of 48 weeks. A decrease in plasma calcitonin and carcinoembryonic antigen levels was seen in 83% and 75% of patients, respectively. Treatment-related adverse events in both trials included diarrhea, fatigue, hypertension, and anorexia.

Axitinib is another oral inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-KIT, but does not target RET. A Phase II trial using axitinib 5 mg twice daily was done in 60 patients with advanced or metastatic thyroid cancer. A partial response was achieved in all histological subtypes, with an objective response rate of 30%, stable disease lasting more than 16 weeks in 38%, and a median progression-free survival of 18.1 months. The effect on serum thyroglobulin concentrations was evaluated in 21 patients, with a decrease noted in most cases, regardless of radiological response. Calcitonin levels were measured in seven patients, and a significant reduction was noted only in the two patients with a partial response. The most common adverse effect was hypertension. Another Phase II trial used axitinib 7 mg twice daily initially and a maximum dose of 10 mg if well tolerated. This trial recruited 52 patients with advanced iodine-refractory DTC or MTC, with a partial response achieved in 34.6% and stable disease in 34.6%. The two main adverse events were hypertension and fatigue.

Sorafenib is an oral inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, RET, c-KIT, and RAF (C-Raf and B-Raf). This drug has been investigated previously in four prospective Phase II trials and shown promising activity in terms of response rate (15%–25%) and median progression-free survival (14–20 months, Table 1). These results led to the design of a pivotal, double-blind, Phase III study known as DECISION, that examined the efficacy and safety of sorafenib 400 mg twice daily versus placebo in 417 patients with progressive radioiodine-refractory DTC. The primary endpoint was met, with significant improvement in median progression-free survival for sorafenib versus placebo (10.8 months versus 5.8 months, hazards ratio 0.587, P<0.0001), maintaining the benefit of sorafenib across different subgroups (eg, regions, age). The objective response rate (including all partial responses) in the sorafenib arm versus the placebo arm was 12.2% versus 0.5%, respectively, the stable disease rate for more than 6 months was 42% versus 33%, with a disease control rate of 54.1% versus 33.8% (P<0.0001). Although the independent central review confirmed a 12% objective response rate by RECIST (Response Evaluation Criteria In Solid Tumors) criteria, most patients (73%) showed some degree of reduction in target tumor lesions. Median overall survival has not been reached, and at the time of analysis, these data are probably affected by the fact that the majority of patients from the placebo group have already or will crossover to the sorafenib group. The most common adverse events in the sorafenib arm included hand-foot syndrome, diarrhea, alopecia, rash, fatigue, weight loss, and hypertension. Dose modifications due to adverse events were required in 77.8% and 30.1% of patients in the sorafenib and placebo groups, respectively. Permanent discontinuation due to adverse events was also more common in the sorafenib group (18.8%) than in the placebo group (3.8%).

Sorafenib was also investigated in a Phase II study of 16 patients with sporadic metastatic MTC. A parallel arm of patients with hereditary MTC was terminated prematurely because of slow patient enrollment. A partial response was seen in only one patient (6.2%), but stable disease beyond 15 months was seen in 50% of patients. Calcitonin and carcinoembryonic antigen levels were measured in 20 patients, with 85% showing a decrease in levels of either marker, but no correlation with radiological response was observed. Adverse events were generally consistent with the known profile of sorafenib. After 12 months of treatment, patients with MTC from a UK study had a radiological objective response rate of 25% and overall survival of 100%. In a retrospective Spanish analysis of 34 patients with advanced and refractory thyroid cancer treated using sorafenib, the objective response rate was 47% for MTC, 19% for DTC, and 33% for ATC. With a median follow-up of 11.5 months, median progression-free survival was 13.5, 10.5, and 4.4 months for MTC, DTC, and ATC respectively.

Sunitinib targets PDGFR, VEGFR, c-Kit, RET, macrophage colony-stimulating factor 1 receptor, and the FLT3 cytokine receptor. Most of the Phase II trials evaluating sunitinib in advanced thyroid cancer have used daily doses of 50 mg on a 4-week on/2-week off schedule (Table 1). Three of the trials included patients with DTC and MTC, and reported objective response rates of 6%–31% and stable disease in 46%–80% of patients. Median progression-free survival was reported in only one of the studies, and was
Another study that included only patients with MTC reported an objective response rate of 35%, with stable disease in 57% of patients and a median progression-free survival of 28 weeks. In this study, RET-activating mutations were found in 85% of the tumors analyzed, and this group was shown to have more durable responses, with a one-year probability of progression-free survival of 88%. The most common treatment-related adverse events were similar in all the trials, and included neutropenia, thrombocytopenia, lymphopenia, hypertension, hand-foot syndrome, fatigue, and gastrointestinal symptoms.

Pazopanib targets the VEGFR family, PDGF, and c-Kit, and was studied at a dose of 800 mg daily in a Phase II study of 39 patients with progressive, radiiodine-resistant DTC. A partial response was reported in 49% of patients and median progression-free survival was 11.7 months. Thyroglobulin concentrations decreased by at least 30% from baseline levels in 88% of 32 patients assessed. The most frequent all-grade adverse events reported were fatigue, changes in skin and hair pigmentation, diarrhea, and nausea. Another Phase II trial was conducted in 16 patients with ATC who were treated with pazopanib 800 mg daily, and found no confirmed RECIST responses, with a median time to progression of 62 days and a median survival time of 111 days.

Vandetanib effectively blocks RET tyrosine kinase, as well as VEGFR-1, VEGFR-2, and the epidermal growth factor receptor. Vandetanib has been assessed at different doses in Phase II and III clinical trials. Two Phase II trials investigated vandetanib in patients with hereditary MTC, and showed objective response rates of 16%–20%, stable disease in 53% of patients, and a median progression-free survival of 27.9 months in the first study using a dose of 300 mg. These results led to a Phase III trial in patients with advanced hereditary or sporadic MTC using 300 mg of vandetanib daily versus placebo. This study recruited 331 patients, with the results showing a significantly prolonged progression-free survival on vandetanib compared with placebo (19.3 months in placebo group versus not reached in vandetanib group, although a predicted median progression-free survival of 30.5 months was obtained using Weibull model, HR: 0.46; 95% CI, 0.31 to 0.69; P<0.001) and a significantly major objective response rate of 45% and 1%, respectively. RET mutation status was positive in 56.5% of patients, negative in 2.4%, and unknown in 41.1%, indicating no correlation between RET mutation status and clinical outcome. The results of this Phase III study led to the US Food and Drug Administration and the European Medicines Agency approving vandetanib as the first systemic treatment for metastatic or progressive MTC in adult patients.

A Phase II trial of vandetanib versus placebo was conducted in 145 patients with advanced DTC. Patients in the vandetanib group had longer progression-free survival than those in the placebo group, with a median progression-free survival of 11.1 months versus 5.9 months, respectively (hazards ratio 0.63). Currently, a double-blind, placebo-controlled Phase III study (VERIFY, NCT01876784) is evaluating the efficacy of vandetanib in advanced, radiiodine-refractory DTC. The most common adverse events for vandetanib in all the trials were clinically insignificant QT interval corrected for heart rate prolongation, diarrhea, rash, nausea, hypertension, asthenia, and fatigue.

Cabozantinib inhibits the hepatocyte growth factor receptor, VEGFR-2, and RET. The clinical benefit of cabozantinib for patients with advanced MTC was observed early in a Phase I study. Its promising clinical activity led to expansion of an MTC-enriched cohort to include 37 patients with MTC, representing 44% of the total study population. In the MTC cohort, a partial response was observed in 29% of patients, along with stable disease for at least 6 months in 41%. The maximum tolerated dose was 175 mg daily, and grade 3 adverse effects comprised hand-foot syndrome and mucositis, along with elevated aspartate aminotransferase, alanine aminotransferase, and lipase.

Following the impressive results of the Phase I study, a Phase III study of cabozantinib 140 mg daily was conducted directly in 330 patients with metastatic MTC. Median progression-free survival was 11.2 months for cabozantinib and 4 months for placebo, with benefit observed across all subgroups according to age, prior TKI treatment, and RET mutation status. The objective response rate was 28% for cabozantinib and 0% for placebo, regardless of RET mutation status. Progression-free survival at one year was 47.3% for cabozantinib and 7.2% for placebo. Common adverse events associated with cabozantinib included diarrhea, hand-foot syndrome, decreased weight, nausea, and fatigue, along with a need for dose reduction in 79% of patients and treatment discontinuation in 16%. The results of the Phase III trial led to US Food and Drug Administration approval of a second multikinase inhibitor for patients with progressive metastatic MTC.

**Lenvatinib**

Lenvatinib (E7080) is an oral multiple RTK inhibitor targeting VEGFR-1-3, FGFR-1-4, RET, c-KIT, and PDGFRβ (Figure 2). Lenvatinib is presently under investigation both
Lenvatinib in thyroid cancer

Lenvatinib was administered orally in escalating doses from 0.2 mg to 32 mg daily in 28-day cycles. The dose-limiting toxicity was grade 3 proteinuria, observed in two patients at 32 mg, and the maximum tolerated dose was defined as 25 mg. The most frequent drug-related toxicities were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%), proteinuria (26%), and vomiting (23%). Dose modifications were required in 49% of patients (most occurring at doses of 12 mg or higher). At the maximum tolerated dose of 25 mg, dose modifications were required in 54% of patients, most commonly due to hypertension and proteinuria. A partial response in terms of antitumor activity was seen in 9% of patients (with renal cell carcinoma, melanoma, or soft tissue sarcoma), with stable disease in 46%.

Pharmacokinetic investigation showed that lenvatinib is absorbed rapidly, reaching peak plasma concentrations in approximately 3 hours, with dose-linear kinetics and no drug interactions as monotherapy and in combination with cytotoxic agents for multiple types of solid tumor, including thyroid carcinoma and hepatocellular carcinoma (in Phase III trials), and melanoma, renal carcinoma, non-small cell lung carcinoma, glioblastoma multiforme, and ovarian and endometrial carcinoma (Phase I and II trials).

The rationale for development of lenvatinib as an antitumor drug lies in its ability to interfere with angiogenesis, one of the main processes involved in survival, local invasion, and metastasis of tumor cells. Lenvatinib targets three of the many extracellular and intracellular molecules capable of modulating angiogenesis and lymphangiogenesis, ie, VEGFR, FGFR, and PDGFRβ. The difference between lenvatinib and other TKIs with antiangiogenesis properties is its potency with regard to inhibition of FGFR-1,56,57 offering a potential opportunity to block one of the well known mechanisms of resistance to VEGF/VEGFR inhibitors. Lenvatinib also has a direct oncogenic effect of controlling tumor cell proliferation by inhibiting RET, c-KIT, and PDGFR beta, and an effect on the tumor microenvironment by blocking FGFR and PDGFR beta (Figure 3 and Table 2).

Phase I trial
The safety, tolerability, and antitumor efficacy of lenvatinib were assessed in a Phase I trial that included 82 patients with advanced, refractory solid tumors (12 colorectal carcinoma, 18 sarcoma, 15 melanoma, eight renal carcinoma, six gastric carcinoma, four pancreatic carcinoma, four mesothelioma, four pancreatic carcinoma, three ovarian carcinoma, three esophageal carcinoma, and others).58 Lenvatinib was administered orally in escalating doses from 0.2 mg to 32 mg daily in 28-day cycles. The dose-limiting toxicity was grade 3 proteinuria, observed in two patients at 32 mg, and the maximum tolerated dose was defined as 25 mg. The most frequent drug-related toxicities were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%), proteinuria (26%) and vomiting (23%). Dose modifications were required in 49% of patients (most occurring at doses of 12 mg or higher). At the maximum tolerated dose of 25 mg, dose modifications were required in 54% of patients, most commonly due to hypertension and proteinuria. A partial response in terms of antitumor activity was seen in 9% of patients (with renal cell carcinoma, melanoma, or soft tissue sarcoma), with stable disease in 46%.

Pharmacokinetic investigation showed that lenvatinib is absorbed rapidly, reaching peak plasma concentrations in approximately 3 hours, with dose-linear kinetics and no drug interactions as monotherapy and in combination with cytotoxic agents for multiple types of solid tumor, including thyroid carcinoma and hepatocellular carcinoma (in Phase III trials), and melanoma, renal carcinoma, non-small cell lung carcinoma, glioblastoma multiforme, and ovarian and endometrial carcinoma (Phase I and II trials).

The rationale for development of lenvatinib as an antitumor drug lies in its ability to interfere with angiogenesis, one of the main processes involved in survival, local invasion, and metastasis of tumor cells. Lenvatinib targets three of the many extracellular and intracellular molecules capable of modulating angiogenesis and lymphangiogenesis, ie, VEGFR, FGFR, and PDGFRβ. The difference between lenvatinib and other TKIs with antiangiogenesis properties is its potency with regard to inhibition of FGFR-1,56,57 offering a potential opportunity to block one of the well known mechanisms of resistance to VEGF/VEGFR inhibitors. Lenvatinib also has a direct oncogenic effect of controlling tumor cell proliferation by inhibiting RET, c-KIT, and PDGFR beta, and an effect on the tumor microenvironment by blocking FGFR and PDGFR beta (Figure 3 and Table 2).

Phase I trial
The safety, tolerability, and antitumor efficacy of lenvatinib were assessed in a Phase I trial that included 82 patients with advanced, refractory solid tumors (12 colorectal carcinoma, 18 sarcoma, 15 melanoma, eight renal carcinoma, six gastric carcinoma, four pancreatic carcinoma, four mesothelioma, four pancreatic carcinoma, three ovarian carcinoma, three esophageal carcinoma, and others).58 Lenvatinib was administered orally in escalating doses from 0.2 mg to 32 mg daily in 28-day cycles. The dose-limiting toxicity was grade 3 proteinuria, observed in two patients at 32 mg, and the maximum tolerated dose was defined as 25 mg. The most frequent drug-related toxicities were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%), proteinuria (26%) and vomiting (23%). Dose modifications were required in 49% of patients (most occurring at doses of 12 mg or higher). At the maximum tolerated dose of 25 mg, dose modifications were required in 54% of patients, most commonly due to hypertension and proteinuria. A partial response in terms of antitumor activity was seen in 9% of patients (with renal cell carcinoma, melanoma, or soft tissue sarcoma), with stable disease in 46%.

Pharmacokinetic investigation showed that lenvatinib is absorbed rapidly, reaching peak plasma concentrations in approximately 3 hours, with dose-linear kinetics and no drug interactions as monotherapy and in combination with cytotoxic agents for multiple types of solid tumor, including thyroid carcinoma and hepatocellular carcinoma (in Phase III trials), and melanoma, renal carcinoma, non-small cell lung carcinoma, glioblastoma multiforme, and ovarian and endometrial carcinoma (Phase I and II trials).

The rationale for development of lenvatinib as an antitumor drug lies in its ability to interfere with angiogenesis, one of the main processes involved in survival, local invasion, and metastasis of tumor cells. Lenvatinib targets three of the many extracellular and intracellular molecules capable of modulating angiogenesis and lymphangiogenesis, ie, VEGFR, FGFR, and PDGFRβ. The difference between lenvatinib and other TKIs with antiangiogenesis properties is its potency with regard to inhibition of FGFR-1,56,57 offering a potential opportunity to block one of the well known mechanisms of resistance to VEGF/VEGFR inhibitors. Lenvatinib also has a direct oncogenic effect of controlling tumor cell proliferation by inhibiting RET, c-KIT, and PDGFR beta, and an effect on the tumor microenvironment by blocking FGFR and PDGFR beta (Figure 3 and Table 2).

Phase I trial
The safety, tolerability, and antitumor efficacy of lenvatinib were assessed in a Phase I trial that included 82 patients with advanced, refractory solid tumors (12 colorectal carcinoma, 18 sarcoma, 15 melanoma, eight renal carcinoma, six gastric carcinoma, four pancreatic carcinoma, four mesothelioma, four pancreatic carcinoma, three ovarian carcinoma, three esophageal carcinoma, and others).58 Lenvatinib was administered orally in escalating doses from 0.2 mg to 32 mg daily in 28-day cycles. The dose-limiting toxicity was grade 3 proteinuria, observed in two patients at 32 mg, and the maximum tolerated dose was defined as 25 mg. The most frequent drug-related toxicities were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%), proteinuria (26%) and vomiting (23%). Dose modifications were required in 49% of patients (most occurring at doses of 12 mg or higher). At the maximum tolerated dose of 25 mg, dose modifications were required in 54% of patients, most commonly due to hypertension and proteinuria. A partial response in terms of antitumor activity was seen in 9% of patients (with renal cell carcinoma, melanoma, or soft tissue sarcoma), with stable disease in 46%.
accumulation after administration for 4 weeks. In a study of the effects of food in eleven patients, no changes in peak plasma levels were observed, but the time to peak plasma levels was longer in the fed group than in the fasted group (5 hours versus 2 hours, respectively).58

**Phase II trials**

On the basis of the Phase I experience and the rationale that expression of FGFR can contribute to control of neoangiogenesis in thyroid cancer, a multicenter, open-label Phase II trial with two different cohorts was initiated. Between October 2008 and February 2010, 58 patients with radioiodine-refractory DTC (74% PTC) were enrolled. All the patients were treated with lenvatinib 24 mg daily. Thirty percent of the patients had received prior anti-VEGFR therapy. The median duration of treatment was 405 days, with a minimum follow-up of 14 months. A partial response was observed in 59% and stable disease in 36%, with a median progression-free survival of 13.3 months (comparable for patients with and without prior VEGFR TKI therapy). The most frequent treatment-related adverse effects were typical of this drug class, ie, hypertension, proteinuria, weight loss, diarrhea, and fatigue, leading to dose reductions in 39% of patients and drug withdrawal in 29%. A decrease in thyroglobulin was observed during the second cycle and was correlated with maximum tumor shrinkage. RAS mutations (NRAS and KRAS) were found in 35% of patients, with a 100% response rate observed in this group and a significantly improved median progression-free survival (80% at 14 months versus 20% in the wild-type RAS group).59

Circulating angiogenic factor levels were assessed at baseline and 8 days post treatment, with significant changes seen in 14 of the 50 circulating angiogenic factors assayed. Increased tumor shrinkage correlated with low baseline levels of angiopoietin-2, and the extent of tumor shrinkage increased with increasing fold changes in fibroblast growth factor-2 and interleukin-10 levels. A significant association was also observed between progression-free survival and low baseline VEGF alpha and angiopoietin-2 levels. Compared with wild-type individuals, patients with KRAS and NRAS mutations had significantly lower VEGF levels and significantly higher soluble Tie-2 levels, suggesting that inherent sensitivity of DTC cells to lenvatinib may be directly linked to KRAS/NRAS mutations, or indirectly through inhibition of VEGF alpha and angiopoietin-2 by induction of soluble Tie-2.60

Fifty-nine patients were enrolled from October 2008 to August 2010 for the MTC cohort of this Phase II trial. The treatment schedule was the same as in the DTC cohort, and 44.1% of patients had previously received anti-VEGF agents. The median duration of treatment was 264 days. No difference in adverse effects was observed between the MTC and DTC cohorts, with 22% of the MTC cohort requiring discontinuation of treatment and dose reduction being needed in 58%. At a minimum of 8 months’ follow-up, 36% of patients had a partial response, 29% had durable stable disease (for more than 23 weeks), median progression-free survival was 9 months (12.9 months in patients without prior VEGF-targeted therapy versus 7.3 months in patients with prior VEGF-targeted therapy), and median overall survival was 16.6 months for the entire MTC study population. Biomarkers were assessed in 24 patients, and a RET mutation was found in 67% of patients; however, this had no correlation with objective response rate or progression-free survival. Clinical benefit in terms of disease control rate (partial response + stable disease) was observed in RET M918T mutant-positive patients, but was not statistically significant. Serum calcitonin and carcinoembryonic antigen levels decreased in all patients and were correlated with response. After the first cycle, a median reduction in calcitonin was documented in 65% of patients with a partial

---

**Table 2** Profile of tyrosine kinase inhibitors in development57

<table>
<thead>
<tr>
<th>TKR</th>
<th>IC50 (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Motesanib</td>
</tr>
<tr>
<td>VEGFR-1</td>
<td>2</td>
</tr>
<tr>
<td>VEGFR-2</td>
<td>3</td>
</tr>
<tr>
<td>VEGFR-3</td>
<td>6</td>
</tr>
<tr>
<td>PDGFβ</td>
<td>84</td>
</tr>
<tr>
<td>c-KIT</td>
<td>8</td>
</tr>
<tr>
<td>RET</td>
<td>59</td>
</tr>
<tr>
<td>RET/PTC</td>
<td>–</td>
</tr>
<tr>
<td>BRAF</td>
<td>–</td>
</tr>
<tr>
<td>Others (IC50)</td>
<td>–</td>
</tr>
</tbody>
</table>

**Abbreviations:** EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFβ, platelet-derived growth factor receptor; TKR, tyrosine kinase receptor; RET, rearranged during transfection tyrosine kinase receptor.
response compared with a 30% reduction in patients with progressive disease. Median carcinoembryonic antigen levels were 46% lower in patients with a partial response compared with a 9% decrease in patients with progressive disease.61

Six circulating angiogenic factors (placenta-derived growth factor, interferon gamma-induced protein 10, VEGF alpha, stromal cell-derived factor-1 alpha, granulocyte colony-stimulating factor, and eotaxin) increased significantly, whereas five circulating angiogenic factors (VEGFR-1-3, angiopoietin-2, and soluble Tie-2) decreased significantly 8 days post treatment. Low baseline levels of angiopoietin-2, soluble Tie-2, hepatocyte growth factor, and interleukin-8 were associated with greater tumor shrinkage and Ang-2, interleukin-8, and hepatocyte growth factor were also associated with prolonged progression-free survival. High baseline levels of VEGF, PDGF-BB, and VEGFR-3 were associated with greater tumor shrinkage.61

Phase III trial
The SELECT trial (NCT01321554) is a multicenter, randomized, double-blind, placebo-controlled study of lenvatinib in radioiodine-refractory DTC patients. The study is planned to treat progressive DTC patients with lenvatinib 24 mg daily or placebo in a randomization ratio of 2:1. The primary endpoints are progression-free survival, secondary objective response rate, and overall survival, with an efficacy evaluation every 8 weeks. Approximately 392 patients have been enrolled in 23 countries (USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Poland, Portugal, Romania, Russia, Spain, Sweden, Thailand, and the UK) and recruitment was completed in October 2012.

Although the SELECT and DECISION trials tested TKIs in the same setting, there were slightly but significant differences between them that should be taken into account when interpreting the data. One of the most important differences is previous therapy, which was not allowed in the DECISION trial but was permitted in the SELECT trial, including one previous treatment with a VEGFR inhibitor. Another noteworthy difference is the centrally confirmed progressive disease prior to inclusion in the SELECT trial, whereas in the DECISION trial this prerequisite was assessed by the investigators (Table 3). These differences could influence progression-free survival and response rates in both arms, making it difficult to compare data between the trials. A recent press release has communicated that the SELECT trial has met the primary endpoint of progression-free survival benefit in treatment of radioiodine-refractory DTC and lenvatinib has been submitted for market authorization worldwide.

Table 3 Differences in study design between DECISION trial (sorafenib versus placebo) and SELECT trial (lenvatinib versus placebo) in patients with progressive radioactive iodine-refractory differentiated thyroid carcinoma

<table>
<thead>
<tr>
<th></th>
<th>DECISION</th>
<th>SELECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects</td>
<td>417</td>
<td>360</td>
</tr>
<tr>
<td>Study period</td>
<td>21 months</td>
<td>36 months</td>
</tr>
<tr>
<td>Randomization</td>
<td>1:1</td>
<td>2:1</td>
</tr>
<tr>
<td>Primary objective</td>
<td>PFS</td>
<td>PFS</td>
</tr>
<tr>
<td>Secondary objectives</td>
<td>ORR, OS</td>
<td>ORR, OS</td>
</tr>
<tr>
<td>Prior anti-VEGFR therapy</td>
<td>No (maximum one)</td>
<td>Prior 14 months</td>
</tr>
<tr>
<td>Evidence of disease progression</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Centrally confirmed radiologic progression prior to randomization</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Tumor evaluation</td>
<td>RECIST 1.0</td>
<td>RECIST 1.1</td>
</tr>
<tr>
<td>Response evaluation by independent central review</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Crossover for placebo patients</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Note: Both are double-blind, randomized, multicenter Phase III trials. Abbreviations: ORR, objective response rate; OS, overall survival; VEGFR, vascular endothelial growth factor receptor; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors.

Conclusion
The multikinase inhibitors represent a shift in the treatment of advanced thyroid cancers, and have achieved prolonged responses and improved progression-free survival. Several agents are being tested, with vandetanib and cabozantinib now approved for the treatment of advanced MTC. Sorafenib and lenvatinib are being assessed for advanced radioiodine-refractory DTC in Phase III clinical trials, with positive results emerging already from the sorafenib trial and recently also for lenvatinib pivotal study. In the near future, we will be faced with a number of treatment options for this patient population, with little evidence for which drug should be used first and whether or not there is crossover drug resistance. Further, in this group of patients, where no chance of cure is possible and TKIs have still not demonstrated a survival benefit, the adverse effects of long-lasting treatment with TKIs could worsen quality of life (which is mostly excellent before starting treatment with these agents). Taking these factors into account, we should be able to choose precisely which patients should be treated with novel targeted therapies. In order to achieve clinical benefit and preserve quality of
life, patients should be better selected, and development of reliable biomarker programs running in parallel with drug development is urgently needed.

Disclosure

The authors report no potential conflicts of interest in this work.

References


